Skip to the page
pepts.wiki

We are not doctors and nothing here is medical advice. Always consult a medical professional first. Why we say this

Studied in peopleStub

ARA-290

Erythropoietin-derived peptide (cibinetide)

An 11 amino acid peptide derived from erythropoietin that does not raise red blood cell counts, studied in small trials of nerve fibre loss.

Reconstitution calculator

At a glance

Studied in people

There are published studies in people. It is not a licensed medicine in the United States or the European Union.

This page is a stub

The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.

How strong is the evidence

How far it has climbed

Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.

  1. Licensed medicine

    A regulator has reviewed the trials and licensed it for a named use.

  2. Phase 3

    Large randomized trials, often thousands of people, against placebo or a standard treatment.

  3. Phase 2

    Mid-sized trials that measure dose against effect in people with the condition.

  4. Phase 1 and early human studies: ARA-290

    First studies in people: safety, and how the body handles it.

  5. Cells and animals

    Laboratory and animal work. An animal result is not a result in people.

77
papers on PubMed
37
of them in people
4
randomized trials
14
reviews

A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16

Handling and reconstitution

From powder to a measured sample

The same four steps for any lyophilized vial. Laboratory handling, not use in a person.

  1. 1. Read the vial

    The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.

  2. 2. Add the diluent

    A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.

  3. 3. Work out the strength

    Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.

  4. 4. Measure the sample

    Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.

The calculator below does the arithmetic and shows its working.

As powder

General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.

In solution

Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.

This is general practice for lyophilized peptides, not data on ARA-290 itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage

Reconstitution calculator

Opens on vial sizes common for research peptides. Change any number. How the arithmetic works

Draw to

10 units

0.1 mL on a U-100 syringe

Concentration
2.5 mg/mL
Each unit holds
25 mcg
Samples in the vial
20
Sample
250 mcg

5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of ARA-290; no amount here is a recommendation.

ARA-290: on PubMed

What PubMed held for ARA-290 on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.

77
papers
37
in humans
5
clinical trials
4
randomized trials
2012: 3 papers122013: 10 papers2014: 10 papers142015: 7 papers2016: 9 papers162017: 7 papers2018: 5 papers182019: 2 papers2020: 3 papers202021: 8 papers2022: 4 papers222023: 2 papers2024: 4 papers242025: 6 papers2026: 6 papers so far26
Papers per year, 2012 to 2026. The most in one year: 10.

Most relevant on PubMed

Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.

  1. The time to develop treatments for diabetic neuropathy

    ReviewRendell MS Expert opinion on investigational drugs, 2021. PMID 33423557

  2. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain

    Randomized trialCulver DA, Dahan A, Bajorunas D, et al. Investigative ophthalmology & visual science, 2017. PMID 28475703

  3. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action

    Randomized trialCerit H, Veer IM, Dahan A, et al. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2015. PMID 26431906

  4. Managing fatigue in sarcoidosis - A systematic review of the evidence

    ReviewAtkins C, Wilson AM Chronic respiratory disease, 2017. PMID 27507833

  5. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density

    Randomized trialDahan A, Dunne A, Swartjes M, et al. Molecular medicine (Cambridge, Mass.), 2013. PMID 24136731

  6. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study

    Randomized trialHeij L, Niesters M, Swartjes M, et al. Molecular medicine (Cambridge, Mass.), 2012. PMID 23168581

  7. Multifaceted roles of a bioengineered nanoreactor in repressing radiation-induced lung injury

    StudyLiu T, Yang Q, Zheng H, et al. Biomaterials, 2021. PMID 34478930

  8. Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus

    StudyHuang B, Jiang J, Luo B, et al. Journal of cellular and molecular medicine, 2018. PMID 29570934

Search used: ("ARA 290"[tiab] OR "ARA290"[tiab] OR cibinetide[tiab]). Run it on PubMed

Research links

Also in Repair and recovery